Abstract
Introduction
Renal cell carcinoma (RCC) is associated with a high rate of metastasis, with approximately one-third of patients already having a metastasis at the time of diagnosis of the primary tumor; another one-third of patients develop a metastasis during follow-up. 1 The most common locations are the lungs, bones, liver, and brain. 2 Metastases to the sinonasal cavity have been reported in less than 1% of all RCC metastases. 2, 3 The development of an RCC metastasis to the sinonasal cavity is classically explained by passage of the malignant cells through the venous shunt created by the Batson plexus, which bypasses pulmonary capillary filtration. 4 However, this hypothesis has been challenged by molecular theories based on the "seed and soil" concept of the metastatic process. 5 ENT surgeons, as well as urologists and oncologists, should be aware of the specific features of RCC metastases in the sinonasal cavity. Severe complications may occur, including massive bleeding, compression of nerve structures, and airway obstruction. 6 The choice between curative therapy and palliative care depends mainly on the general prognosis.
Most RCC metastases to the sinonasal cavity have been described in isolated case reports. Our primary the primary RCC in 3 patients (37.5%); these metastases were isolated in 1 patient and associated with other metastases in 2 patients. In the remaining 5 patients, the sinonasal metastasis appeared between 1 and 21 years after diagnosis of the primary RCC.
Metastasis to the sinonasal cavity appeared in the context of known disseminated disease in 3 cases. It was the initial presentation of a disseminated recurrence in 1 case and was isolated in 1 case. Metastases were also diagnosed in the lung, bone, adrenal gland, and tongue.
Primary and disseminated disease. The stage of the primary renal tumor was T1 in 2 patients, T2 in 3 patients, T3 in 2 patients, and not documented in 1. The primary tumor's Fuhrman grade was 2 in 3 patients, 3 in 2 patients, 4 in 2 patients, and undocumented in 1 patient.
Treatment of the primary tumor. All but 1 patient underwent a nephrectomy for the primary tumor, either at first presentation or after the diagnosis of the sinonasal cavity metastasis was made. The lone unoperated patient, the aforementioned 53-year-old man, received palliative care, owing to his poor general health status and the presence of a massive metastasis in the skull base. Four patients were administered one or more systemic therapies for their disseminated disease; these agents included sunitinib, everolimus, bevacizumab, objective was to report our findings with 8 consecutively presenting patients who were diagnosed with RCC metastatic to the sinonasal cavity. Our secondary aim was to perform a comprehensive review of all published cases of sinonasal RCC metastases.
Case series
We conducted this retrospective, multicenter study at two French tertiary care referral centers. We identified 9 cases of RCC metastatic to the sinonasal cavity during the preceding 10 years. Data were insufficient for 1 patient, so he was excluded. We then compiled information on demographic variables, clinical characteristics, imaging, treatment, and follow-up for the remaining 8 patients (a summary of cases in table form can be obtained from the corresponding author by email request). Our 8 patients included 6 men and 2 women, aged 55 to 86 years (mean: 66.9; median: 63.5). Our study protocol was approved by the Institutional Review Board of the Bordeaux University Hospital.
Diagnosis. The patients' primary complaints were nasal obstruction, epistaxis, and diplopia. One patient, a 53-year-old man, exhibited symptomatic hypercalcemia. A reddish endonasal mass was identified on nasal endoscopy in 7 patients.
On computed tomography (CT), the lesions exhibited osteolysis and strong enhancement after contrast injection (figure, A). Magnetic resonance imaging (MRI) demonstrated hypo-and isointensity on both T1-and T2-weighted images, as well as strongly enhanced lesions after gadolinium injection (figure, B and C). Flow voids also were reported.
Biopsy with general anesthesia was performed in every case. Extensive bleeding occurred in 4 patients and required compression and nasal packing.
Pathologic examination led to the diagnosis of metastatic renal clear-cell carcinoma in every case. A Fuhrman grade was reported in 5 cases; all were classified as Fuhrman grade 2. When tested, the tumors were positive for vimentin, EMA, CD10, and CKAE1/AE3, and they were negative for CK7. Thoracic, abdominal, and pelvic CTs were obtained in each case to locate the primary tumor and to screen for other metastases.
Tumor characteristics. The metastases were located in the ethmoid sinus (n = 3), nasal cavity (n = 2), sphenoid sinus (n = 2), and maxillary sinus (n = 1). Identification of the metastasis led to the diagnosis of and anti-PD-L1. Two patients received local treatments for other metastases with surgery, radiotherapy, and/ or radiofrequency ablation.
Treatment of the metastasis. The choice of treatment for the sinonasal metastases was determined during a multidisciplinary (head/neck and urology) tumor board meeting.
Six of the 8 patients had a resectable metastasis, and it was decided to treat their lesions with surgery after the primary tumor had been treated (if the primary had not already been treated). Arteriography and embolization were performed in 4 cases before surgery to avoid bleeding (figure, D). The internal and external carotid arteries were involved in the vascularization of the lesions through the ethmoid, facial, and sphenopalatine branches. Only the external carotid branches were embolized.
Exclusively endoscopic removal of the metastasis was achieved in 4 of these 6 patients. The other 2 were treated with a combined endoscopic and craniofacial resection (external transfrontal approach) because their lesions were located in the ethmoid sinus in proximity to the orbit and the dura and they had invaded the lateral part of the frontal sinus. Adjuvant intensity-modulation radiotherapy was administered to 4 of the operated patients.
One of the 2 unoperated patients had an unresectable lesion, and the other's general health was too poor to allow for surgery. Both patients received palliative radiotherapy.
Follow-up and recurrence. Follow-up ranged from 0.6 to 39.9 months (mean: 30.7 ± 35.9).
A complete local response was achieved in 4 patients treated with surgery and radiotherapy; however, 2 of these 4 patients died of disseminated disease beyond the head and neck region. Two patients developed a local recurrence and were treated with surgery and/or radiotherapy. Of the 2 patients managed with palliative care, the 53-year-old man died as a result of the extension of his sphenoid sinus metastasis to the skull base; as for the other patient, a 55-year-old man, the size of his metastasis remained stable after radiotherapy and systemic treatment.
Literature review
We conducted a MEDLINE literature search using the keywords renal cell cancer, renal carcinoma, hypernephroma, sinus, nose, head and neck, metastasis, and distant. Our search period extended from January 1996 through January 2016. The search retrieved 66 articles, from which we removed 15 articles because they were in a language other than English and 9 others that we were not able to access.
The remaining 42 articles covered a total of 53 cases. Of these, we excluded 3 articles covering 8 cases: in 3 of these cases the metastasis had not originated in the sinonasal cavity and in 5 cases the data were insufficient (e.g., a lack of information about the primary tumor, the location of the metastasis, or treatment). This left us with 39 articles 2,4,6-42 covering 45 cases, to which we added our 8 cases.
Statistical analyses were performed with GraphPad Prism v. 6.01 for Windows (GraphPad Software; San Diego). A p value of <0.05 was considered to be statistically significant.
Population and disease characteristics. The 53 patients included 40 men and 13 women, aged 40 to 87 years (mean: 59.9 ± 12).
RCC had been previously diagnosed in 29 patients (54.7%); 17 of them were in remission, 10 had an additional metastasis beyond their sinonasal metastasis, and 2 were currently being treated for a primary RCC diagnosed less than 1 year earlier. The delay between the diagnosis of the primary and the diagnosis of the metastasis in the sinonasal cavity ranged from 1 month to 21 years (mean: 7.35 ± 5.8 yr). Some 39.3% of recurrences were diagnosed more than 10 years after the diagnosis of the primary.
The sinonasal metastasis was the first presentation of RCC in 24 patients (45.3%). In 4 of these patients, the metastasis was the first presentation of a contralateral RCC in a patient who had already been treated for a first RCC 7 to 15 years before.
The metastases were located in the nasal cavity in 23 patients (43.4%), the ethmoid sinus in 14 (26.4%), the sphenoid sinus in 10 (18.9%), the frontal sinus in 3 (5.7%), and the maxillary sinus in 3. The orbit had been invaded in 14 cases (26.4%) and the skull base in 12 cases (22.6%). Some 24 patients (45.3%) had a synchronous metastasis associated with their sinonasal metastasis, and 29 patients (54.7%) had an isolated metastasis. These concurrent metastases were located in the lung in 12 patients; in bone in 10 patients; in the adrenal gland in 3 patients; in the thyroid, tongue, liver, and contralateral kidney in 2 patients each; and in the pancreas, skin, pharynx, and thymus in 1 patient each (some patients had extranasal metastases at more than one site).
The precise location of the metastasis in the sinonasal cavity was isolated in 14 of the 24 patients in whom the metastasis was the first presentation and in 8 of the 17 patients whose previously diagnosed RCC was in remission. The remaining patients had a metachronous metastasis. The most common symptoms leading to the diagnosis of metastasis in the sinonasal cavity were nasal bleeding in 29 patients (54.7%) and nasal obstruction in 20 (37.7%) (table 1).
Treatment of the primary tumor.
The management of the primary tumor involved a nephrectomy in 38 cases (71.7%), systemic therapy alone in 11 cases (20.8%), and palliative treatment in 4 cases (7.5%).
Treatment of the metastasis. Surgery on the metastatic lesion was performed in 35 cases (66.0%) (table 2). Thirteen patients were operated on with endoscopic endonasal surgery alone, 8 with craniofacial resection alone, 3 with a combined endoscopic and craniofacial resection, and 1 with palliative surgery; information on the surgical modality was not available for 10 patients. Embolization was performed before surgery in 12 of the 35 cases (34.3%) to prevent bleeding and during surgery in 1 case to manage massive bleeding.
Follow-up.
Follow-up data on local status were available in 31 patients and on general status in 33 patients (table 2) .
With respect to local status, the duration of follow-up ranged from to 0.6 to 112 months (mean: 25.1 ± 26.4). There was a strong statistically significant association between surgery and a complete local response (p < 0.0001). No significant difference in local response was found between patients who underwent surgery alone and those who underwent surgery and received radiotherapy (p = 1.0). Concerning general status, follow-up again ranged from to 0.6 to 112 months (mean: 25.0 ± 25.5).
No difference in overall survival curves was found between local treatment and no local treatment (p = 0.19) or between systemic treatment and no systemic treatment (p = 0.32). However, overall survival was significantly better for patients who had isolated vs. multiple metastases (p = 0.013). There was no difference in overall survival between patients whose sinonasal metastasis represented the first presentation of RCC and those who had already been diagnosed with RCC (p = 0.95).
Discussion
Much wisdom concerning RCC metastatic to the sinonasal cavity is to be found in the literature. These metastases are rare and have been primarily published as isolated case reports. To be accepted for publication, those cases had to exhibit original characteristics, which may explain the high proportion of metastases as the first presentation of RCC in the published cases, where the diagnosis of RCC was usually made by an otorhinolaryngologist rather than by a urologist.
Metastases from a distant tumor account for 0.21 to 2.1% of all oromaxillofacial tumors. 43, 44 In our study, ENT surgeons were more likely than urologists to report such atypical tumors, since they were listed as the first author in 64% of the published reports in our review. Urologists may encounter an RCC metastasis in the sinonasal cavity during regular follow-up with CT and positron-emission tomography. These metastases are referred to ENT surgeons only if they are symptomatic or require local treatment with a curative or palliative intent. Small asymptomatic metastases that remain stable during follow-up or that are widely disseminated may not appear to be sufficiently relevant for publication, so the number of RCC metastases to the sinonasal cavity may be underestimated.
Metastases are a common occurrence in the course of RCC, developing in two-thirds of RCC patients.
1,2 Some authors believe that RCCs are the most common tumors that metastasize to the sinonasal cavity. 8, 45 RCCs have been identified as the primary tumor in 39.6 to 48.8% of cases of a distant metastasis to the sinonasal cavity. 45, 46 According to a study by Choong et al, which included 912 consecutively presenting patients, locations in the sinonasal cavity account for fewer than 1% of all RCC metastases, which is far lower than the rate for lung, bones, and liver metastases. 2 Franzen et al recently reported a similar incidence, with only 1 of 612 RCC patients (0.16%) having a metastasis in the sinonasal cavity.
3 However, these rates are far lower than the rates of 15% found in case reports and frequently quoted from unidentified sources. 4, 8, 10 In our review of 53 cases, the metastasis to the sinonasal cavity represented the first presentation of RCC in 45.3% of patients and was diagnosed during urologic follow-up in 54.7% of patients. These rates are similar to those found in the literature for bony metastases of RCC. 1 In cases where the primary tumor had been diagnosed before the metastasis, the mean delay between the diagnosis of the primary and the diagnosis of the sinonasal metastasis was 7.35 years in our review; the reported delay for bony metastases was only 3 years. 1 A late recurrence of tumor is a common topic in published case reports. In our review, 39.3% of recurrences were diagnosed more than 10 years after the primary had been diagnosed.
It is not yet established whether an RCC metastasis to the sinonasal cavity should be classified as a bony metastasis or a mucosal metastasis. Sinonasal tumors, including metastases, tend to be asymptomatic for a long period. They exert pressure on the bony walls as they grow in such a way that it is not possible to accurately determine the site of their origin.
There is a lack of consensus in the literature as to whether metastases in the sinonasal cavity are usually isolated or are usually synchronous with other metastases. 2, 9 In our review, more than half of the patients had an isolated metastasis. Only 5 patients had another metastasis in the head and neck region: thyroid gland (n = 2), tongue (n = 2), and pharyngeal wall (n = 1). 11, 16, 27, 35 Symptoms of RCC metastasis to the sinonasal cavity vary according to the location of the tumor. In our review of 53 cases, the most common site of RCC metastasis was the nasal cavity (43.4%). In these patients, contact with the nasal cavity mucosa often led to nasal bleeding, which was the most common symptom (54.7%). A high incidence of nasal bleeding is found in most series in the literature, ranging from 33 to 65%. 6, 8, 45 The potential of an RCC metastasis to bleed can be assessed by imaging. RCC metastases usually appear as a solid mass with peripheral bone destruction and wall displacement, and they are highly enhanced on CT after contrast injection. 8, 13 MRI shows hypo-and isointensity on both T1 and T2 weighting; the lesions strongly enhance after gadolinium injection. Flow voids may be seen in such tumors, and they are indicative of a high risk for bleeding. 13 In some cases, bleeding may be life-threatening. 8, 15, 26 If an RCC metastasis is suspected, a biopsy should be performed carefully with general anesthesia. 18 Guidelines and recommendations state that the choice of treatment strategies will depend on the history of the primary RCC as well as the number of metastases and their location. 16, 28, 47 Metastasectomy is indicated for single and resectable RCC metastases in selected patients. 47, 48 Our review found that surgical treatment was associated with a significantly higher percentage of complete local responses than were other strategies. This finding is in agreement with those reported for other locations of RCC metastases. 48, 49 External, endoscopic endonasal, and combined approaches can be used depending on the location and extension of the tumor. 8, 10 Preoperative embolization is effective in avoiding massive blood loss during surgery on an RCC bony metastasis. 50 It provides better visibility for the surgeon, shortens operating time, and allows for better tumor resection. Embolization is recommended before biopsy or surgery on a sinonasal cavity metastasis. 10, 16, 28 Even so, preoperative embolization was performed in only 34.3% of the surgical patients in our review; no mentions were made of any increase in perioperative morbidity. Embolization may be required (1) if CT or MRI demonstrates a highly vascularized lesion, (2) in cases of spontaneous bleeding, (3) when an endoscopic endonasal approach is taken, and/or (4) in patients with cardiovascular comorbidities.
The role of postoperative radiotherapy has been debated; our review found that it had no effect on survival. 8, 21 Surgery and radiotherapy are indicated in palliative situations to avoid recurrent bleeding, to avoid airway obstruction and cranial nerve compression, and to improve quality of life. 10, 18, 20, 40 Systemic therapy is recommended in the event of multiple or unresectable metastases. 9, 28, 36 In our review, survival was significantly better in patients who had a single metastasis than in those with multiple metastases, as has been the case with RCC metastases to other sites. 47 In conclusion, ENT surgeons, urologists, and oncologists should be aware of the characteristics of RCC metastases to the sinonasal cavity. Curative surgery should be considered during urologic tumor board meetings for isolated RCC metastases to the sinonasal cavity. Unilateral nasal bleeding or nasal obstruction in a patient with a history of RCC may represent the first sign of a sinonasal metastasis, even long after treatment of the primary. Before obtaining a biopsy, an ENT surgeon who is faced with a highly vascularized sinonasal tumor should consider the possibility of a primary RCC and look for it with abdominal imaging.
